141,500 Shares in CytomX Therapeutics, Inc. $CTMX Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 141,500 shares of the biotechnology company’s stock, valued at approximately $531,000.

A number of other large investors have also recently added to or reduced their stakes in CTMX. BlackRock Inc. acquired a new position in CytomX Therapeutics during the 2nd quarter worth $65,849,000. Bank of America Corp DE raised its stake in shares of CytomX Therapeutics by 1,064.3% in the 1st quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company’s stock valued at $47,953,000 after purchasing an additional 9,326,480 shares in the last quarter. Orbimed Advisors LLC bought a new position in shares of CytomX Therapeutics during the second quarter worth about $19,208,000. Commodore Capital LP bought a new position in shares of CytomX Therapeutics during the second quarter worth about $17,462,000. Finally, Perceptive Advisors LLC acquired a new position in CytomX Therapeutics in the second quarter worth about $15,876,000. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $3.72 on Thursday. The company’s fifty day moving average is $3.48 and its two-hundred day moving average is $3.98. CytomX Therapeutics, Inc. has a 1-year low of $1.90 and a 1-year high of $8.21. The stock has a market capitalization of $810.59 million, a price-to-earnings ratio of -7.44 and a beta of 2.14.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The business had revenue of $1.42 million during the quarter, compared to analyst estimates of $12.39 million. Sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.4 EPS for the current fiscal year.

Analysts Set New Price Targets

CTMX has been the subject of several research analyst reports. Zacks Research lowered CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. JPMorgan Chase & Co. reduced their target price on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, August 13th. Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Guggenheim decreased their target price on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CytomX Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.90.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.